Wyeth Pharmaceuticals, a division of Wyeth, announced that the US Food and Drug Administration (FDA) has approved Pristiq (desvenlafaxine), a structurally novel, once-daily serotonin-norepinephrine reuptake inhibitor (SNRI), to treat adult patients with major depressive disorder (MDD).
Wyeth expects to begin shipping Pristiq to wholesalers beginning in the second quarter of 2008.
“We are pleased to be able to bring Pristiq to patients,” said Bernard Poussot, President and Chief Executive Officer of Wyeth. “Pristiq is Wyeth’s fourth new drug to receive approval in the last twelve months, demonstrating our ability to achieve success through the rigorous scientific process of discovery and development.
“Pristiq is an important new therapeutic option for patients and clinicians because no single therapy works for all people with major depression,” said Philip Ninan, MD, Vice President of Wyeth Medical Affairs, Neuroscience.
“Pristiq is approved at a once-daily 50-mg dose that does not require titration, allowing physicians to start their patients at the recommended therapeutic dose. We are encouraged by the tolerability profile seen in clinical studies.”
FDA approval was subject to several post-marketing commitments, including conducting and submitting data from a new long-term maintenance (relapse prevention) study, a sexual dysfunction study, paediatric studies and a study exploring lower doses. The agency also requested an additional non-clinical toxicity study.
The efficacy of Pristiq as a treatment for depression was established in four 8-week, randomised, double-blind, placebo-controlled, fixed-dose studies in adult outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for MDD. At the recommended dose of 50 mg, the discontinuation rate due to an adverse experience for Pristiq (4.1 percent) was similar to the rate for placebo (3.8 percent).
Side effects of many antidepressant therapies can cause some patients to stop taking their medication. The most commonly observed adverse reactions in patients taking Pristiq for MDD in short-term, fixed-dose studies (incidence >5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence (sleepiness), decreased appetite, anxiety, and specific male sexual function disorders.